Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

HERO Trial Suggests Relugolix to Become New Standard for T-Suppression in Advanced Prostate Cancer

May 30th 2020

Relugolix (Relumina) demonstrated superiority over leuprolide (Lupron) in sustained testosterone (T)-suppression through 48 weeks in patients with advanced prostate cancer.

Phase II TheraP Trial Shows Promise for LuPSMA in mCRPC

May 29th 2020

Results from the TheraP trial found that in men with metastatic castration resistant prostate cancer who progressed after treatment with docetaxel, 177Lu-PSMA-617 was more active than cabazitaxel.

NCCN Adds Rucaparib to Prostate Cancer Guidelines

May 28th 2020

The National Comprehensive Cancer Network has updated its Prostate Cancer guidelines to include the PARP inhibitor rucaparib.

Study Links Decline in PSA Screening to Increased Incidence of Advanced Prostate Cancer

May 25th 2020

Decreases in local-stage and increases in distant- and regional-stage prostate cancer incidence may be the result of a recommendation by the US Preventive Services Task Force against PSA–based screenings.

Rucaparib Prostate Cancer Approval Sets Stage for Further Research

May 21st 2020

Alan H. Bryce, MD, discusses the recent regulatory approval of rucaparib in metastatic castration-resistant prostate cancer and explains how the approval has underscored the importance of genetic testing in the field.

Meta-Analysis Finds Adding ADT to EBRT Extends Survival in Localized Prostate Cancer

May 21st 2020

External beam radiotherapy plus androgen deprivation therapy showed superior overall survival compared with EBRT plus a brachytherapy boost in men with intermediate- and high-risk prostate cancer.

Dr. Klein on Oncotype DX in Predicting Outcomes in African Americans With Prostate Cancer

May 21st 2020

Eric A. Klein, MD, discusses the utility of Oncotype DX Genomic Prostate Score in predicting outcomes in African American men with prostate cancer.

FDA Approves Multiple Companion Diagnostics for Olaparib in HRR+ mCRPC

May 20th 2020

The FDA has approved the FoundationOneCDx and BRACAnalysis CDx tests as companion diagnostics to identify patients with metastatic castration-resistant prostate cancer with homologous recombination repair mutations, making them eligible for treatment with the PARP inhibitor olaparib.

Dr. Klein on Oncotype DX in Predicting Outcomes in African Americans With Prostate Cancer

May 20th 2020

Eric A. Klein, MD, discusses the utility of Oncotype DX Genomic Prostate Score in predicting outcomes in African American men with prostate cancer.

Agarwal Outlines Importance of Olaparib Approval in HRR-Mutant mCRPC

May 20th 2020

Neeraj Agarwal, MD, provides insight into olaparib, further discusses the data that led to the regulatory approval, and shares the implications of this approval in metastatic castration-resistant prostate cancer.

Agarwal Outlines Importance of Olaparib Approval in HRR-Mutant mCRPC

May 20th 2020

Neeraj Agarwal, MD, provides insight into olaparib, further discussed the data that led to the regulatory approval, and shared the implications of this approval in metastatic castration-resistant prostate cancer.

Dr. Bryce on the FDA Approval of Rucaparib in BRCA-Mutant mCRPC

May 20th 2020

Alan H. Bryce, MD, discusses the accelerated approval of rucaparib (Rubraca) for the treatment of adult patients with BRCA mutation (germline and/or somatic)–associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor–directed therapy and a taxane-based chemotherapy.

Dr. Klein on the Importance of the Importance of Prognostic Genomic Assays in Prostate Cancer

May 20th 2020

Eric A. Klein, MD, discusses the importance of providing genomic testing to patients with prostate cancer.

Dr. Jain on the Use of Diagnostic Tracers in Prostate Cancer

May 19th 2020

Manoj K. Jain, MD, discusses diagnostic tracers in prostate cancer.

Dr. Kohli on the Use of Enzalutamide and Apalutamide in mHSPC

May 19th 2020

Manish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Vogelzang: Rucaparib Approval Raises New Hope in mCRPC

May 16th 2020

Nicholas J. Vogelzang, MD, discusses the significance of the rucaparib approval for this patient population.

Dr. Koo on the Need for Next-Generation Imaging in Prostate Cancer

May 16th 2020

Phillip J. Koo, MD, discusses the need for next-generation imaging in prostate cancer.

Dr. Vargas on Research With Proton Therapy in Prostate Cancer

May 16th 2020

Carlos E. Vargas, MD, discusses research with proton therapy in prostate cancer.

FDA Approves Rucaparib for BRCA+ mCRPC

May 15th 2020

The FDA has approved rucaparib for the treatment of adult patients with BRCA-mutant recurrent, metastatic castration-resistant prostate cancer.

Dr. Penson on Ongoing Research in Prostate Cancer

May 15th 2020

David F. Penson, MD, MPH, MMHC, discusses ongoing research in prostate cancer.